Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy

Cancer Discovery(2021)10.1158/2159-8290.cd-20-0756Source: DataRank Database

A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy is a research paper published in Cancer Discovery (2021). On theSindex it has a DataRank of 4.2. It has been cited 210 times, with 100 citing works in its 1-hop citation network.

N/A

4.2DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access210 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

gen nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02348216

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 10.70)OA: bronzeTopics (52)Linked Datasets (8)DataCite Reuse (8)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 19%Citation Network 81%

Base Score Contribution

0.803

From this paper's citation signal

Citation Network Contribution

3.4

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study
Leukemia & lymphoma/Leukemia and lymphoma202124 citations12 referencesContributes 0.268
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
Blood202515 citations22 referencesContributes 0.126
Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma
Journal of Hepatology202460 citations39 referencesContributes 0.105
Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma
Haematologica202329 citations33 referencesContributes 0.103
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
Journal for ImmunoTherapy of Cancer202325 citations32 referencesContributes 0.102

Authors (17)

Jonathan Boiarsky ORCID,Gvantsa Pantsulaia ORCID,Judit Svensson‐Arvelund ORCID,Matthew Lin ORCID,Aleksandra Wroblewska ORCID

Live enrichment

PubMed:33334730 PMC:PMC7933082 OpenAlex:https://openalex.org/W3111766121

NIH

Grant: P30CA196521

NIH

Grant: 5T32GM007280

NIH

Grant: 5T32AI007605

NIH

Grant: R01CA154947

NIH

Grant: R01CA190400

NIH

Grant: R01AT011326

NIH

Grant: R01AI113221

NIH

Grant: R33CA223947

NIH

Grant: U19AI128949

NIH

Grant: R37CA246239

NIGMS NIH HHS

Grant: T32 GM007280

NIAID NIH HHS

Grant: T32 AI007605

Damon Runyon Cancer Research Foundation

Grant: CI-76-14

Merck Investigator Studies Program

Cancer Research Institute

Damon Runyon Cancer Research Foundation

FWCI

10.70

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

bronze

journalhttps://aacrjournals.org/cancerdiscovery/article-pdf/11/3/599/1838403/599.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/11/3/599/1838403/599.pdf

journalhttps://doi.org/10.1158/2159-8290.cd-20-0756

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33334730

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7933082

Fields of Study

CAR-T cell therapy researchImmunotherapy and Immune ResponsesVirus-based gene therapy researchAnimalsAntigens, NeoplasmBystander EffectCD8-Positive T-LymphocytesCRISPR-Cas SystemsCytotoxicity, ImmunologicDisease Models, AnimalGene EditingGenetic EngineeringHumansImmunotherapyImmunotherapy, AdoptiveMiceMice, KnockoutNeoplasmsReceptors, Chimeric AntigenT-Cell Antigen Receptor SpecificityT-LymphocytesTreatment OutcomeXenograft Model Antitumor Assaysfas Receptor

MeSH Terms

Gene EditingReceptors, Chimeric AntigenAnimalsAntigens, NeoplasmCytotoxicity, ImmunologicDisease Models, AnimalGenetic EngineeringHumansImmunotherapyNeoplasmsT-LymphocytesImmunotherapy, AdoptiveTreatment OutcomeMice, KnockoutCD8-Positive T-Lymphocytesfas ReceptorXenograft Model Antitumor AssaysBystander EffectT-Cell Antigen Receptor SpecificityMiceCRISPR-Cas Systems

Keywords

ImmunotherapyCancer researchT cellImmunologyBiologyMedicineImmune system

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma

10.6084/m9.figshare.23557990.v1figshare

Additional file 1 of HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma

10.6084/m9.figshare.23557990figshare

Additional file 2 of HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma

10.6084/m9.figshare.23557993.v1figshare

Additional file 2 of HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma

10.6084/m9.figshare.23557993figshare

Additional file 3 of HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma

10.6084/m9.figshare.23557996.v1figshare

Additional file 3 of HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma

10.6084/m9.figshare.23557996figshare

Additional file 1 of FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer

10.6084/m9.figshare.26581793.v1figshare

Additional file 1 of FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer

10.6084/m9.figshare.26581793figshare